A major limitation to GvHD research is that diagnosis relies on clinical features and biopsy of the involved tissues. A major advance in the field of GvHD diagnosis and prediction has been the identification and validation of a series of GvHD biomarkers that promise to revolutionize the ability to manage GvHD. Proteomic studies have identified serum or plasma protein markers to predict non-relapse mortality and acute GvHD. 1 Especially ST2, 2,3 Reg3α 4 and TNFR1 5 are promising biomarkers to predict transplant outcomes in multiple cohorts of allogeneic stem cell transplantation (allo-SCT). 6, 7 However, before biomarker measurements can be applied widely as a reproducible diagnostic tool, reliable and standardized biomarker assays are needed as suggested by the NIH consensus. 8 An ideal GvHD diagnostic, prognostic or predictive test for routine use should provide a high level of discrimination between patients with and without GvHD, have adequate sensitivity, high specificity and reproducibility. In addition, the assay should be rapid, easy to perform, widely available and affordable. Here, we evaluated a new multiplex microfluidic channel assay system adapted to measure GvHD biomarkers and compared it with a conventional ELISA.
In a single institution retrospective study, we analyzed plasma samples collected from 21 patients with hematologic malignancies who underwent T-cell depleted HLA-matched sibling allo-SCT with an ex vivo CD34 + selected graft and survived beyond day 100 post transplant (Protocol 13-H-0144, ClinicalTrials. gov Identifier: NCT01866839). The conditioning regimen included cyclophosphamide, fludarabine and myeloablative TBI. Low-dose, short-course cyclosporine was used as GvHD prophylaxis for 21 days. Plasma samples were collected at day 14 and day 28 post transplant. The concentrations of ST2, Reg3α and TNFR1 in plasma samples were measured using two protein quantification strategies: an automatic multiplex microfluidic channel system (Simple Plex, Protein Simple, San Jose, CA, USA) and a single-analyte ELISA (ST2, TNFR1, R&D, Minneapolis, MN, USA; Reg3α, MBL, Woburn, MA, USA) under similar conditions. The coefficient of variation (CV) was calculated as the ratio of the SD to the mean to measure the repeatability and reproducibility of each assay. Pearson's correlation was used to assess the association between the assays. Mann-Whitney test was used to compare the assay levels between subgroups of patients. All tests were two-sided and a P-value o0.05 was considered to be statistically significant. Data analyses were performed using Prism Version 6 software (GraphPad, Inc., La Jolla, CA, USA) and R statistical software 3.2.3 (R Foundation for Statistical Computing, Vienna, Austria).
The median age at transplant was 48 years (range, 11-73) and 62% were females. Primary hematologic malignancies included AML or myelodysplastic syndrome (71%), ALL (24%) and nonHodgkin's lymphoma/CLL (5%). Five patients (24%) had a hematopoietic cell transplantation comorbidity index of 3 or higher.
9,10 At a median follow-up of 17 months (range 3-28), the cumulative incidences of grade 0-II and grade III-IV acute GvHD (days to onset of acute GvHD, range 15-42) were 81 and 19%, respectively. Seven subjects (33%) required high-dose steroids (⩾1 mg/kg of methylprednisolone or equivalent dose) for the treatment of acute GvHD and only one patient developed steroid refractory GvHD (Supplementary Table 1 ).
The microfluidic channel system generally had a lower interassay coefficient of variation (%CV) in comparison with ELISA when control healthy donor samples (n = 5) were repetitively measured (Table 1 , %CV, mean ± SD: ST2, 40.3 ± 22.1 in microfluidic assay versus 43.4 ± 14 in ELISA; Reg3α, 27 ± 21 versus 59.8 ± 26.1; and TNFR1, 29.9 ± 18.6 versus 41.2 ± 13.6, respectively). Three biomarker values measured at day 14 or day 28 were all significantly correlated between the two assays (Pearson's correlations between two assays at day 14, day 28 were: ST2, 0.75, 0.82; Reg3α, 0.65, 0.44; and TNFR1, 0.54, 0.63, respectively, Supplementary Figure 1) . Although ST2 levels at day 14 in this cohort was not associated with the grade of acute GvHD (Figure 1) , levels of ST2 at day 28 were significantly higher in the patients with grade III-IV acute GvHD in comparison with those patients with grade 0-II acute GvHD for both ELISA and microfluidic channel system assays ( Figure 1 , P = 0.049 and P = 0.011, respectively). This observation implies the importance of fold changes in ST2 levels between day 14 and day 28 for the development of severe acute GvHD. Comparisons of other performance parameters between assays are summarized in Table 1 . Importantly, although test costs were comparable, the plasma sample size required in the microfluidic channel system was smaller and the assay time was shorter (1-2 h) compared with ELISA assay (16 h). In summary, we found that automatic multiple microfluidic channel system is more rapid and subject to less variability compared with the standard ELISA methods. Day 28 ST2 levels measured by both ELISA and microfluidic channel system are associated with high-grade acute GvHD. The microfluidic channel system has the characteristics and potential to be used as a standardized assay to measure GvHD biomarkers. The utility of this new assay system merits validation in a large transplant cohort in a multicenter study. Currently, the cost of the microfluidic channel assay is comparable to that of the ELISA assay. However, the cost of a fully validated commercialized kit of the microfluidic channel assay is likely to fall, so the cost-effective analysis should be considered in future study. . ST2 level at day 14 and day 28, and its association to severity of GvHD.
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